<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885885</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-08-04</org_study_id>
    <secondary_id>EudraCT: 2008-006766-28</secondary_id>
    <nct_id>NCT00885885</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases</brief_title>
  <acronym>PLANET</acronym>
  <official_title>An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-only Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the combination of&#xD;
      Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects&#xD;
      with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2009-2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients whose disease becomes resectable</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resection</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease relapse following surgery.</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of molecular predictive markers for response.</measure>
    <time_frame>2009-2013</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab+FOLFOX 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab+FOLFIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab+FOLFOX-4</intervention_name>
    <description>Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.&#xD;
A cycle of panitumumab is defined as 14 days.&#xD;
FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:&#xD;
Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle&#xD;
Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2&#xD;
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2&#xD;
5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab+FOLFIRI</intervention_name>
    <description>Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.&#xD;
A cycle of panitumumab is defined as 14 days.&#xD;
FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:&#xD;
Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle&#xD;
Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing&#xD;
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1&#xD;
5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman &gt; 18 years &lt; 75 of age&#xD;
&#xD;
          -  Competent to comprehend, sign, and date an IEC-approved informed consent form&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  Wild Type KRAS status&#xD;
&#xD;
          -  Metastatic colorectal carcinoma exclusively affecting only the liver, compliant with&#xD;
             one of the following criteria&#xD;
&#xD;
               1. Number of liver metastasis ≥ 4.&#xD;
&#xD;
               2. Size of one liver metastasis &gt; 10 cm in diameter.&#xD;
&#xD;
               3. Liver metastases technically not resectable.&#xD;
&#xD;
          -  At least 1 uni-dimensionally measurable lesion&#xD;
&#xD;
          -  Patients with the following characteristics will be included:&#xD;
&#xD;
               1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or&#xD;
                  capecitabine +/- radiotherapy with a disease-free interval &gt; than 6 months after&#xD;
                  its completion; or after oxaliplatin containing adjuvant treatment with a&#xD;
                  disease-free interval &gt; than 12 months&#xD;
&#xD;
               2. Recurrence after surgical treatment and/or radiotherapy with no adjuvant systemic&#xD;
                  treatment.&#xD;
&#xD;
               3. De novo diagnosis of the disease.&#xD;
&#xD;
          -  Patients with simultaneous liver metastases are eligible, if the primary tumor has&#xD;
             been resected at least 1 month prior chemotherapy.&#xD;
&#xD;
          -  Prior radiotherapy is acceptable.&#xD;
&#xD;
          -  Patients deemed to have no major contra-indication to liver surgery from a general&#xD;
             health perspective.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70%&#xD;
&#xD;
          -  Adequate bone marrow function: neutrophils ≥ 1.5 x109/ L; platelets ≥ 100 x109/&#xD;
             L;hemoglobin ≥ 9g/ dL&#xD;
&#xD;
          -  Hepatic and metabolic function as follows:&#xD;
&#xD;
        Total bilirubin count ≤ 1.5 x ULN and not increasing more than 25% within the last 4 weeks;&#xD;
        ALAT and ASAT &lt; 5 x ULN;&#xD;
&#xD;
          -  Renal function, calculated creatinine clearance or 24 hour creatinine clearance ≥ 50&#xD;
             mL/ min.&#xD;
&#xD;
          -  Magnesium &gt; LLN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr&#xD;
             tyrosine kinase inhibitors (eg, erlotinib).Subjects who have experienced an infusion&#xD;
             reaction to their first dose of anti-EGFR therapy (cetuximab) may participate in this&#xD;
             clinical trial.&#xD;
&#xD;
          -  Surgery (not including diagnostic biopsy) and/or radiotherapy in the 4 weeks prior to&#xD;
             inclusion in the study.&#xD;
&#xD;
          -  Metastasis on any site other than the liver, including extrahepatic lymph nodes.&#xD;
&#xD;
          -  Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of&#xD;
             the skin or pre-invasive carcinoma of the skin.&#xD;
&#xD;
          -  Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved&#xD;
             proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion&#xD;
&#xD;
          -  Unresolved toxicities from prior systemic therapy that, in the opinion of the&#xD;
             investigator, does not qualify the patient for inclusion&#xD;
&#xD;
          -  Significant cardiovascular disease including unstable angina or myocardial infarction&#xD;
             within 6 months before initiating study treatment or a history of ventricular&#xD;
             arrhythmia&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial&#xD;
             pneumonitis or pulmonary fibrosis on baseline chest CT scan&#xD;
&#xD;
          -  Treatment for systemic infection within 14 days before initiating study treatment&#xD;
&#xD;
          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea&#xD;
             (defined as &gt; 4 loose stools per day)&#xD;
&#xD;
          -  History of Gilbert's syndrome or dihydropyrimidine deficiency&#xD;
&#xD;
          -  History of any medical condition that may increase the risks associated with study&#xD;
             participation or may interfere with the interpretation of the study results&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,&#xD;
             chronic active hepatitis B infection&#xD;
&#xD;
          -  subject allergic to the ingredients of the study medication or to Staphylococcus&#xD;
             protein A&#xD;
&#xD;
          -  Any co-morbid disease that would increase risk of toxicity&#xD;
&#xD;
          -  Any kind of disorder that compromises the ability of the subject to give written&#xD;
             informed consent and/or comply with the study procedures&#xD;
&#xD;
          -  Any investigational agent within 30 days before enrolment&#xD;
&#xD;
          -  Must not have had a major surgical procedure within 28 days of randomization&#xD;
&#xD;
          -  Subject who is pregnant or breast feeding&#xD;
&#xD;
          -  Woman or man of childbearing potential not consenting to use adequate contraceptive&#xD;
             precautions i.e. double barrier contraceptive methods (eg diaphragm plus condom), or&#xD;
             abstinence during the course of the study and for 6 months after the last study drug&#xD;
             administration for women, and 1 month for men&#xD;
&#xD;
          -  Subject unwilling or unable to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Abad, MD, phD</last_name>
    <role>Study Chair</role>
    <affiliation>ICO-H. Germans Trial i Pujol. Badalona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Carrato, MD, phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospial Ramón y Cajal. Madrid. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>FOLFOX-4</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

